Company profile
Aura Biosciences, Inc.
NASDAQ:AURABiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BELZUPACAP SAROTALOCAN | phase2 | — | 3 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05483868 | phase1 | active_not_recruiting | 2022-09-26 | 2027-03-01 | Aura Biosciences | A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer |
| NCT06007690 | phase3 | active_not_recruiting | 2023-12-06 | 2027-11-15 | Aura Biosciences | A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma |
| NCT04417530 | phase2 | completed | 2020-08-05 | 2024-04-22 | Aura Biosciences | Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma |
| NCT03052127 | phase1_2 | completed | 2017-02-27 | 2021-01-26 | Aura Biosciences | Study in Subjects With Small Primary Choroidal Melanoma |
| NCT06643884 | phase2 | recruiting | 2024-12-16 | 2026-11-30 | Aura Biosciences | Suprachoroidal Administration in Subjects With Metastases to the Choroid |
FDA applications (0)
No records yet.